Provided by Tiger Trade Technology Pte. Ltd.

Avrobio Inc.

16.80
0.0000
Volume:- -
Turnover:289.39K
Market Cap:754.22M
PE:24.91
High:16.80
Open:16.80
Low:16.80
Close:16.80
52wk High:19.80
52wk Low:10.56
Shares:44.89M
Float Shares:30.86M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6744
EPS(LYR):0.2743
ROE:42.73%
ROA:-35.18%
PB:8.49
PE(LYR):61.26

Loading ...

Company Profile

Company Name:
Avrobio Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.